Resmed inc. announces results for the second quarter of fiscal year
2019
San diego--(business wire)--resmed inc. (nyse: rmd, asx: rmd), a world-leading connected health company, today announced results for its quarter ended december 31, 2018. second quarter 2019 highlights revenue increased 8% to $651.1 million; up 9% on a constant currency basis gross margin expanded 70bps to 58.9% net operating profit increased 8%; non-gaap operating profit up 15% gaap diluted earnings per share of $0.86; non-gaap diluted earnings per share of $1.00 “we had a solid quarter with top-line growth and gross margin expansion, as well as continued fiscal discipline to drive leverage and improved operating profit,” said mick farrell, resmed’s ceo. “our new airfit f30 and airfit n30i masks have been launched in many markets, and mask sales are growing well globally. during the quarter we further expanded our software and device ecosystems, through the acquisitions of matrixcare and propeller health, to provide digital health solutions to millions more people worldwide. we are empowering people to live healthier and happier lives where they live, and we are doing this by providing innovative software, services, and solutions to improve outcomes, create efficiencies, and reduce overall healthcare system costs.” financial results and operating metrics unaudited; $ in millions, except for per share amounts december 31,2018 december 31,2017 constantcurrency (a) 58.2 december 31,2018 december 31,2017 constantcurrency (a) discussion of second quarter results revenue in the u.s., canada, and latin america, excluding software as a service, grew by 9 percent compared to the prior year period, driven by strong sales across our mask and device product portfolios. revenue in combined europe, asia and other markets grew by 1 percent on a constant currency basis compared to the same period of the prior year. mask sales were strong across these markets. as expected, device sales in france and japan were impacted as customers completed their connected device upgrade programs. device sales outside france and japan grew well. software as a service revenue increased by 63 percent, compared to the prior year period, due to continued growth in our brightree service offerings and incremental contribution from the acquisition of matrixcare, which closed in the second quarter and healthcarefirst, which closed in the first quarter. gross margin expanded by 70 basis points over the prior year period, primarily due to benefits from manufacturing and procurement efficiencies, product mix changes and higher margin contribution from matrixcare, partially offset by declines in average selling prices. selling, general and administrative expenses increased by 6 percent compared to the prior year period, or by 8 percent on a constant currency basis. excluding the impact of recent acquisitions, selling, general and administrative expenses increased by 4 percent on a constant currency basis. sg&a expenses improved to 24.8 percent of revenue in the quarter, compared with 25.2 percent in the same period of the prior year. income from operations increased by 8 percent and non-gaap income from operations increased by 15 percent compared to the prior year period. net income increased by 1,208 percent, predominantly attributable to the one-time transition tax recognized in the prior year quarter, and non-gaap net income remained stable compared to the prior year period. non-gaap measures adjust for amortization of acquired intangibles, matrixcare deferred revenue, acquisition-related expenses, and the impact of u.s. tax reform. gaap diluted earnings per share increased by 1,129 percent, predominantly attributable to the one-time transition tax recognized in the prior year quarter, and non-gaap diluted earnings per share remained stable compared with the same period of the prior year. cash flow from operations for the quarter was $129.5 million, compared to net income in the current quarter of $124.6 million. during the quarter we paid $52.8 million in dividends. other business and operational highlights completed the acquisition of matrixcare, a leader in software solutions for more than 15,000 providers across skilled nursing, life plan communities, senior living and private duty, for consideration of $750.0 million. commenced the previously announced joint venture with verily, combining resmed’s expertise in sleep apnea and verily’s advanced health data analytics technologies, to study the health and financial impacts of undiagnosed and untreated sleep apnea, and to develop software solutions that enable healthcare providers to more efficiently identify, diagnose, treat and manage individuals with sleep apnea and other breathing-related sleep disorders. announced the acquisition of propeller health, a digital therapeutics company providing connected health solutions for people living with chronic obstructive pulmonary disease (copd) and asthma, for $225.0 million. the transaction closed on january 7, 2019. through brightree, acquired apacheta corporation, a cloud-based software as a service provider offering mobile applications that empower companies to automate and streamline processes in route sales, field marketing, pick-up and delivery, transportation, and field services. named one of america’s top 100 corporate citizens for the third straight year by forbes and just capital. resmed ranked #18 out of 890 large publicly traded u.s. companies, and #1 out of 32 “health care equipment & services” companies. share repurchase program we have temporarily suspended our repurchase program due to recent acquisitions. accordingly, we did not repurchase any shares during the three months ended december 31, 2018. dividend program the resmed board of directors today declared a quarterly cash dividend of $0.37 per share. the dividend will have a record date of february 7, 2019, payable on march 14, 2019. the dividend will be paid in u.s. currency to holders of resmed’s common stock trading on the new york stock exchange. holders of chess depositary instruments trading on the australian securities exchange will receive an equivalent amount in australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between cdis and nyse shares. the ex-dividend date will be february 6, 2019 for common stockholders and for cdi holders. resmed has received a waiver from the asx’s settlement operating rules, which will allow resmed to defer processing conversions between its common stock and cdi registers from february 6, 2019 through february 7, 2019, inclusive. webcast details resmed will discuss its second quarter fiscal year 2019 results on its webcast at 1:30 p.m. u.s. pacific time today. the live webcast of the call can be accessed on resmed’s investor relations website at investor.resmed.com. please go to this section of the website and click on the icon for the “q2 2019 earnings webcast” to register and listen to the live webcast. a replay of the earnings webcast will be accessible on our website and available approximately two hours after the live webcast. in addition, a telephone replay of the conference call will be available approximately two hours after the webcast by dialing +1 800-585-8367 (u.s.) or +1 416-621-4642 (outside u.s.), and entering the passcode 6179558. the telephone replay will be available until february 7, 2019. about resmed at resmed (nyse: rmd, asx: rmd) we pioneer innovative solutions that treat and keep people out of the hospital, empowering them to live healthier, higher-quality lives. our cloud-connected medical devices transform care for people with sleep apnea, copd and other chronic diseases. our comprehensive out-of-hospital software platforms support the professionals and caregivers who help people stay healthy in the home or care setting of their choice. by enabling better care, we improve quality of life, reduce the impact of chronic disease and lower costs for consumers and healthcare systems in more than 120 countries. to learn more, visit resmed.com and follow @resmed. safe harbor statement statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the private securities litigation reform act of 1995. these forward-looking statements – including statements regarding resmed’s projections of future revenue or earnings, expenses, new product development, new product launches, new markets for its products, the integration of acquisitions, litigation, and tax outlook – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. additional risks and uncertainties are discussed in resmed’s periodic reports on file with the u.s. securities & exchange commission. resmed does not undertake to update its forward-looking statements. condensed consolidated statements of income (unaudited; $ in thousands, except for per share amounts) december 31,2018 december 31,2017 december 31,2018 december 31,2017 $ (1) see the reconciliation of non-gaap financial measures in the table at the end of the press release. resmed inc. and subsidiaries (unaudited; $ in thousands) december 31,2018 (unaudited; $ in thousands) december 31,2018 december 31,2017 (unaudited; $ in thousands, except for per share amounts) the measure, “non-gaap income from operations” is reconciled with gaap income from operations below: december 31,2018 december 31,2017 december 31,2018 december 31,2017 december 31,2018 december 31,2017 december 31,2018 december 31,2017 (unaudited; $ in thousands, except for per share amounts) december 31,2018 december 31,2017 constantcurrency (a) december 31,2018 december 31,2017 constantcurrencygrowth (a) (a)
